PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2
Status:
Recruiting
Trial end date:
2022-09-29
Target enrollment:
Participant gender:
Summary
PrEvention of posttraumatic contractuRes with Ketotifen 2 (PERK 2) is a Phase III randomized,
controlled, double blinded multicenter trial with 3 parallel groups (Ketotifen 2 mg or 5 mg
or lactose placebo twice daily orally for 6 weeks) and a primary endpoint of elbow
extension-flexion range of motion (ROM) arc at 12 weeks post-randomization.